Limitations, agreements, and source contact

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma · Source last updated 2018-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Roche has discontinued further development of the Notch inhibitor (RO4929097) and this Phase II trial was prematurely closed.

point Of Contact

email

gounderm@mskcc.org

organization

Memorial Sloan Kettering Cancer Center

phone

646-888-4167

title

Dr. Mrinal Gounder

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice